CFTR and cystic fibrosis: The KONDUCT trial (NCT01614457) assessed the safety and efficacy of Ivacaftor in 69 CF patients aged 6 years or older with at least one copy of the R117H-CFTR mutation, which is present in 3% of all CF patients and produces defects in both gating and conductance (class III and IV mutations, respectively) [16].